X

Drug Profile

Alprostadil - Pfizer

Alternative Names: Caverject; Prostaglandin E1 - Pfizer

Latest Information Update: 23 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
Mechanism of Action Prostaglandin E1 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Erectile dysfunction

Most Recent Events

16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
13 Jul 2001 A study has been added to the adverse events and Men's Health therapeutic trials sections
05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com